Sara A. Hurvitz, MD, FACP

Dr. Sara A. Hurvitz MD, FACP
Faculty Member

Sara A. Hurvitz, MD, FACP

Senior Vice President and Director
Clinical Research Division, Fred Hutch

Clinical Research Division, Fred Hutch

Fax: 206.667.6936
Mail Stop: D5-310

Dr. Sara Hurvitz is a medical oncologist and clinical research leader who is senior vice president of the Clinical Research Division at Fred Hutch and head of the Division of Hematology and Oncology at the University of Washington Department of Medicine. A graduate of the Keck School of Medicine at the University of Southern California, Hurvitz is an international expert in breast oncology and a leader in clinical and laboratory-based oncology research, with extensive experience leading clinical trials in all phases. Dr. Hurvitz works to boost the national reputation of the solid tumor clinical research program and oversees the continued growth of clinical research programs in stem cell transplantation and cell therapy, hematologic cancers and nonmalignant hematology. Dr. Hurvitz has contributed extensively to the growth of clinical research programs since joining the University of California, Los Angeles as a resident in 1999. She is a member of the American College of Physicians, the American Society of Hematology, the American Society of Clinical Oncology, American Association for Cancer Research, the European Society of Medical Oncology and the American College of Physicians.

Other Appointments & Affiliations

Professor and Head, Division of Hematology and Oncology
Department of Medicine, University of Washington School of Medicine


University of California, Los Angeles, Hematology/Oncology Fellowship, completed 2006

University of California, Los Angeles, Internal Medicine Internship and Residency, completed 2002

University of Southern California, 1999, MD

University of California, Irvine, 1993, BS (Biology), BA (Psychology)

Research Interests

Preclinical evaluation of novel targeted therapeutics for breast cancer

Development of first-in-human phase I clinical trials of new cancer therapies

Phase II-III clinical trials for breast cancer

Triple negative breast cancer

HER2+ breast cancer

HER2-low breast cancer

Hormone receptor positive breast cancer

Targeted therapies for breast cancer

Clinical Expertise

Medical (medicinal) oncology management of breast cancer including early stage and late stage disease, neoadjuvant treatments, novel targeted therapies against HER2, estrogen receptor positive and triple negative breast cancer. Immune based treatments for breast cancer.

Find a Clinical Trial

Dr. Hurvitz in the News

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email or call 206.667.2210